Description

Imagine watching cells rewrite their proteome live, protein by protein. That's the power of BONCAT (bioorthogonal non-canonical amino acid tagging). Using azidonorleucine (ANL), researchers can label newly synthesized proteins and track de novo protein production as it happens—turning the invisible machinery of life into something we can see, measure, and understand.

One of the most compelling applications of ncAA technology reveals how oxytocin can reverse cancer cachexia—the devastating muscle wasting that affects up to 80% of advanced cancer patients and resists conventional nutrition interventions. Using BONCAT, scientists discovered that cancer shuts down de novo protein synthesis in skeletal muscle. But oxytocin flips the switch.

Citation: Sviercovich et al., 2025

BONCAT (bioorthogonal non-canonical amino acid tagging) uses azidonorleucine (ANL) to label newly synthesised proteins in living cells. ANL is incorporated in place of methionine during translation, and its azide group allows selective chemical capture of only those proteins made during the labelling window. This enables researchers to track de novo protein synthesis in real time.

Using BONCAT, researchers discovered that cancer cachexia, the muscle wasting that affects up to 80% of advanced cancer patients, is driven by a shutdown of de novo protein synthesis in skeletal muscle. Oxytocin treatment restored protein synthesis, revealing a potential therapeutic intervention for a condition that resists conventional nutritional approaches (Sviercovich et al., 2025).

This research application of ncAAs differs from therapeutic incorporation: here, the ncAA serves as a molecular reporter rather than a functional enhancement. It demonstrates the breadth of ncAA utility, from fundamental biology research tools to therapeutic building blocks, all enabled by the same genetic code expansion technology.

Source publication